Human papillomavirus vaccine - Soligenix

Drug Profile

Human papillomavirus vaccine - Soligenix

Latest Information Update: 08 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Soligenix
  • Class Cancer vaccines; Papillomavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Human papillomavirus infections

Most Recent Events

  • 02 Jun 2015 Immunogenicity data from a preclinical trial in Human papillomavirus infections (Prevention) released by Soligenix
  • 02 Jun 2015 Preclinical trials in Human papillomavirus infections (Prevention) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top